A Preliminary Evaluation of N-acetylcysteine's Effects on Patient Adherence to Treatment for Cocaine Use Disorder

Overview

Journal Ment Health Clin

Specialty Psychiatry

Date 2023 Mar 9

PMID 36891481

Authors

Jake Schechter

Geoffrey W Brown

Maria Janda

Affiliations

Soon will be listed here.

Abstract

Introduction: Cocaine use disorder (CUD) is a disabling disease associated with high rates of relapse and intense cravings. Patients with CUD struggle to adhere to treatment, which contributes to relapse and frequent readmissions to residential rehab (RR) facilities. Preliminary studies suggest that N-acetylcysteine (NAC) attenuates cocaine-induced neuroplasticity and, therefore, may assist with cocaine abstinence and adherence to treatment.

Methods: This retrospective cohort study obtained data from 20 RR facilities across Western New York. Eligible subjects were 18 or older, diagnosed with CUD, and were divided based on their exposure to 1200 mg NAC twice daily during RR. The primary outcome was treatment adherence measured by outpatient treatment attendance rates (OTA). Secondary outcomes included length of stay (LOS) in RR and craving severity on a 1 to 100 visual analog scale.

Results: One hundred eighty-eight (N = 188) patients were included in this investigation: NAC, n = 90; control, n = 98. NAC did not significantly impact OTA (% appointments attended), NAC 68%; control 69%, ( = .89) or craving severity NAC 34 ± 26; control 30 ± 27, ( = .38). Subjects treated with NAC had a significantly longer average LOS in RR compared with controls, NAC 86 ± 30; control 78 ± 26, ( = .04).

Discussion: In this study, NAC did not impact treatment adherence but was associated with a significantly longer LOS in RR for patients with CUD. Owing to limitations, these results may not be applicable to the general population. More rigorous studies examining NAC's impact on treatment adherence in CUD are warranted.

References

Amen S, Piacentine L, Ahmad M, Li S, Mantsch J, Risinger R . Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology. 2010; 36(4):871-8. PMC: 3052624. DOI: 10.1038/npp.2010.226. View

Kiluk B, Babuscio T, Nich C, Carroll K . Smokers versus snorters: do treatment outcomes differ according to route of cocaine administration?. Exp Clin Psychopharmacol. 2013; 21(6):490-8. PMC: 3943602. DOI: 10.1037/a0034173. View

Karila L, Petit A, Lowenstein W, Reynaud M . Diagnosis and consequences of cocaine addiction. Curr Med Chem. 2012; 19(33):5612-8. DOI: 10.2174/092986712803988839. View

Spronk D, van Wel J, Ramaekers J, Verkes R . Characterizing the cognitive effects of cocaine: a comprehensive review. Neurosci Biobehav Rev. 2013; 37(8):1838-59. DOI: 10.1016/j.neubiorev.2013.07.003. View

LaRowe S, Kalivas P, Nicholas J, Randall P, Mardikian P, Malcolm R . A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict. 2013; 22(5):443-52. PMC: 4348575. DOI: 10.1111/j.1521-0391.2013.12034.x. View

LaRowe S, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A . Is cocaine desire reduced by N-acetylcysteine?. Am J Psychiatry. 2007; 164(7):1115-7. DOI: 10.1176/ajp.2007.164.7.1115. View

Mardikian P, LaRowe S, Hedden S, Kalivas P, Malcolm R . An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 31(2):389-94. DOI: 10.1016/j.pnpbp.2006.10.001. View

Schmaal L, Veltman D, Nederveen A, van den Brink W, Goudriaan A . N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology. 2012; 37(9):2143-52. PMC: 3398721. DOI: 10.1038/npp.2012.66. View

Woodcock E, Lundahl L, Khatib D, Stanley J, Greenwald M . N-acetylcysteine reduces cocaine-seeking behavior and anterior cingulate glutamate/glutamine levels among cocaine-dependent individuals. Addict Biol. 2020; 26(2):e12900. PMC: 10369173. DOI: 10.1111/adb.12900. View

10.

Kampman K . The treatment of cocaine use disorder. Sci Adv. 2019; 5(10):eaax1532. PMC: 6795516. DOI: 10.1126/sciadv.aax1532. View

11.

Schmidt H, Pierce R . Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction. Ann N Y Acad Sci. 2010; 1187:35-75. PMC: 5413205. DOI: 10.1111/j.1749-6632.2009.05144.x. View

12.

Harris A, Kivlahan D, Barnett P, Finney J . Longer length of stay is not associated with better outcomes in VHA's substance abuse residential rehabilitation treatment programs. J Behav Health Serv Res. 2011; 39(1):68-79. DOI: 10.1007/s11414-011-9250-2. View

13.

Deepmala , Slattery J, Kumar N, Delhey L, Berk M, Dean O . Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015; 55:294-321. DOI: 10.1016/j.neubiorev.2015.04.015. View

14.

Echevarria M, Andrade Reis T, Ruffo Capatti G, Siciliano Soares V, da Silveira D, Fidalgo T . N-acetylcysteine for treating cocaine addiction - A systematic review. Psychiatry Res. 2017; 251:197-203. DOI: 10.1016/j.psychres.2017.02.024. View

15.

LaRowe S, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K . Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006; 15(1):105-10. PMC: 1513138. DOI: 10.1080/10550490500419169. View

16.

Goldstein R, DesLauriers C, Burda A, Johnson-Arbor K . Cocaine: history, social implications, and toxicity: a review. Semin Diagn Pathol. 2009; 26(1):10-7. DOI: 10.1053/j.semdp.2008.12.001. View

17.

Trivedi M, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T . Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021; 384(2):140-153. PMC: 8111570. DOI: 10.1056/NEJMoa2020214. View

18.

Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D . Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis. J Gen Intern Med. 2019; 34(12):2858-2873. PMC: 6854210. DOI: 10.1007/s11606-019-05074-8. View

19.

Cartwright W . Cocaine medications, cocaine consumption and societal costs. Pharmacoeconomics. 2004; 18(4):405-13. DOI: 10.2165/00019053-200018040-00008. View

20.

Froeliger B, McConnell P, Stankeviciute N, McClure E, Kalivas P, Gray K . The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study. Drug Alcohol Depend. 2015; 156:234-242. PMC: 4633320. DOI: 10.1016/j.drugalcdep.2015.09.021. View